Artizan Biosciences

Artizan Biosciences identifies and distinguishes bacteria in the gut that predispose people to disease with the goal of developing new and potentially curative treatments for unmet medical needs. This unique approach is applicable to a variety of microbiota-driven diseases including inflammatory bowel disease (IBD), central nervous system disorders, obesity, metabolic syndrome, and autoimmune disease. Founded to advance the IgA-SEQ™ technology platform of renowned immunologists Richard Flavell, PhD, Noah Palm, PhD, and Marcel R. de Zoete, PhD, Artizan’s lead program focuses on IBD, a group of inflammatory conditions of the small intestine and colon including ulcerative colitis and Crohn’s disease. Artizan Biosciences is located adjacent to Yale University at Science Park in New Haven, CT.

Artizan’s vision is to cure and protect people from diseases with a basis in the microbiome.

Artizan’s mission is to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies.